Literature DB >> 8687162

Topographical immunohistochemical expression of bcl-2 protein in human liver lesions.

A Skopelitou1, M Hadjiyannakis, V Alexopoulou, O Krikoni, S Kamina, N Agnantis.   

Abstract

Immunolocalization of the bcl-2 protein was investigated in 60 hepatocellular carcinomas, 10 cholangiocarcinomas. 15 metastatic adenocarcinomas as well as in 37 non-neoplastic liver lesions. The three-step immunoperoxidase method was performed in archival, routinely processed material. bcl-2 protein was not identified either in neoplastic, dysplastic or normal hepatocytes, whereas it was observed in bile ductules and small bile duct epithelia, but not in the epithelium lining large bile ducts. All cases of cholangiocarcinoma and 60% of metastatic adenocarcinomas were bcl-2 positive. bcl-2 appears to be an additional marker in distinguishing hepatocellular carcinoma from cholangiocarcinoma or metastatic adenocarcinoma. Also, bcl-2 does not seem to be involved in human liver hepatocyte survival.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687162

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

2.  Serine 574 phosphorylation alters transcriptional programming of FOXO3 by selectively enhancing apoptotic gene expression.

Authors:  Z Li; J Zhao; I Tikhanovich; S Kuravi; J Helzberg; K Dorko; B Roberts; S Kumer; S A Weinman
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

3.  The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium.

Authors:  A C Okaro; A R Deery; R R Hutchins; B R Davidson
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Detection of bcl-2 and bax expression and bcl-2/JH fusion gene in intrahepatic cholangiocarcinoma.

Authors:  Lin-Lang Guo; Sha Xiao; Ying Guo
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

5.  Expresssion of bcl-2 oncoprotein in cases of acute and chronic viral hepatitis type B and type C: a clinicopathologic study.

Authors:  Athanassios C Tsamandas; Konstantinos Thomopoulos; Charalambos Gogos; Konstantinos Tepetes; Theodore Kourelis; Panagiota Ravazoula; Theodore Petsas; Dionissis S Bonikos; Chrisoula Karatza; Dionissios D Karavias
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

6.  Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia.

Authors:  Sheng-Mian Li; Shu-Kun Yao; Nobuyoshi Yamamura; Toshitsugu Nakamura
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 7.  Genetic and molecular abnormalities in cholangiocarcinogenesis.

Authors:  Victor J Hassid; Frank A Orlando; Ziad T Awad; Dongfeng Tan; Thaer Khoury; Bestoun H Ahmed; Sadir J Alrawi
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

8.  Characterization and isolation of ductular cells coexpressing neural cell adhesion molecule and Bcl-2 from primary cholangiopathies and ductal plate malformations.

Authors:  L Fabris; M Strazzabosco; H A Crosby; G Ballardini; S G Hubscher; D A Kelly; J M Neuberger; A J Strain; R Joplin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

9.  Altered expression of cellular Bcl-2 in the progression of hamster cholangiocarcinogenesis.

Authors:  Byung-Suk Jeon; Byung-Il Yoon
Journal:  ScientificWorldJournal       Date:  2012-04-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.